The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Approved BTK Inhibitor Without Covalent Bond for CLL.

2.

New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.

3.

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

4.

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

5.

Brain cancer: a Q&A session.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot